Eads & Heald Wealth Management Has $1 Million Stake in Bristol Myers Squibb Company $BMY

Eads & Heald Wealth Management grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 12.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,659 shares of the biopharmaceutical company’s stock after buying an additional 2,482 shares during the quarter. Eads & Heald Wealth Management’s holdings in Bristol Myers Squibb were worth $1,003,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Vest Financial LLC boosted its stake in Bristol Myers Squibb by 73.5% in the first quarter. Vest Financial LLC now owns 16,912 shares of the biopharmaceutical company’s stock valued at $1,031,000 after buying an additional 7,166 shares in the last quarter. Pines Wealth Management LLC grew its position in Bristol Myers Squibb by 8.2% in the first quarter. Pines Wealth Management LLC now owns 4,559 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 345 shares during the last quarter. Gateway Investment Advisers LLC raised its stake in Bristol Myers Squibb by 0.4% during the first quarter. Gateway Investment Advisers LLC now owns 111,991 shares of the biopharmaceutical company’s stock worth $6,830,000 after acquiring an additional 436 shares in the last quarter. Finally, Sivia Capital Partners LLC lifted its holdings in shares of Bristol Myers Squibb by 9.3% in the first quarter. Sivia Capital Partners LLC now owns 4,691 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 399 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Citigroup decreased their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $56.38.

Insider Activity

In related news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $45.39 on Monday. The stock’s 50 day moving average is $46.36 and its 200 day moving average is $48.49. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The firm has a market cap of $92.38 billion, a P/E ratio of 18.30, a P/E/G ratio of 2.32 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the business earned $2.07 EPS. The company’s revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.5%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.